FutureTech II Acquisition Corp.
FTII evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for FTII—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
Market Cap
$51.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2025.
Run FutureTech II Acquisition Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available FutureTech II Acquisition Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Financials
Short Interest
as of May 21, 2026- % of float
- 0.0%
- Days to cover
- 0.0
- Shares short
- 129
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FTII short interestGovernance
Frequently asked questions
Who is the CEO of FutureTech II Acquisition Corp.?
Mr. Ray Lei Chen is the chief executive officer of FutureTech II Acquisition Corp. (FTII).
Where is FutureTech II Acquisition Corp. headquartered?
FutureTech II Acquisition Corp. (FTII) is headquartered in New Rochelle, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.